Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study

Nathalie De Castro, Alexandre Brun, Pierre Sellier, Gwenn Hamet, Frédéric Mechaï, Valérie Garrait, Amélie Chabrol, Marie-Anne Bouldouyre, Eric Froguel, Didier Troisvallets, Pauline Caraux-Paz, Constance Delaugerre, Willy Rozenbaum, Jean-Michel Molina

Open source

DOI: 10.1186/s12981-022-00499-4
Published: 2023-01-03
Container: AIDS Research and Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12981-022-00499-4,
  title = {Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study},
  author = {Nathalie De Castro and Alexandre Brun and Pierre Sellier and Gwenn Hamet and Frédéric Mechaï and Valérie Garrait and Amélie Chabrol and Marie-Anne Bouldouyre and Eric Froguel and Didier Troisvallets and Pauline Caraux-Paz and Constance Delaugerre and Willy Rozenbaum and Jean-Michel Molina},
  year = {2023},
  journal = {AIDS Research and Therapy},
  doi = {10.1186/s12981-022-00499-4},
  url = {https://doi.org/10.1186/s12981-022-00499-4}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study
AU  - Nathalie De Castro
AU  - Alexandre Brun
AU  - Pierre Sellier
AU  - Gwenn Hamet
AU  - Frédéric Mechaï
AU  - Valérie Garrait
AU  - Amélie Chabrol
AU  - Marie-Anne Bouldouyre
AU  - Eric Froguel
AU  - Didier Troisvallets
AU  - Pauline Caraux-Paz
AU  - Constance Delaugerre
AU  - Willy Rozenbaum
AU  - Jean-Michel Molina
PY  - 2023
JO  - AIDS Research and Therapy
DO  - 10.1186/s12981-022-00499-4
UR  - https://doi.org/10.1186/s12981-022-00499-4
ER  -

APA

Castro, N. D., Brun, A., Sellier, P., Hamet, G., Mechaï, F., Garrait, V., Chabrol, A., Bouldouyre, M., Froguel, E., Troisvallets, D., Caraux-Paz, P., Delaugerre, C., Rozenbaum, W., & Molina, J. (2023). Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study. AIDS Research and Therapy. https://doi.org/10.1186/s12981-022-00499-4

Source records

crossref · retrieved 2026-09-27T02:21:04.965Z